GoAI
Get started
Immunovant, Inc. logo

Immunovant, Inc.

IMVT

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$44.37

+$0.02 · +0.05%

Aug 21, 4:00 PM ET

IMVT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

33

Expensive

Momentum

71

Gaining

Sentiment

53

Mixed

Risk resilience

69

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Eric Venker
Listed since
Jun 21, 2019
Employees
315

Market position

Day range

Current $44.37

52-week range

Current $44.37

Open
$44.635
Previous close
$44.35
Volume
846.6K
0.52× average
Average volume
1.63M
Average daily volume
Market cap
9.16B USD
Beta
0.81
Market reference 1
50-day average
$39.2708
+12.98% above average
200-day average
$29.6647
+49.57% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.63B USD
EV / EBITDA
-7.19×
Earnings yield
-11.16%
Free cash flow yield
-8.99%

Profitability & efficiency

Return on equity
-59.30%
Return on assets
-52.80%
Return on invested capital
-62.46%

Financial health

Current ratio
9.09×

Financial statements

Income trends

Operating income

−532.9M USD-21.62%

Net income

−505.61M USD-22.17%
Income trends across reported periods−118.35M USD−269.09M USD−419.84M USD−570.59M USDOperating income, FY2022: −156.03M USDOperating income, FY2023: −208.28M USDOperating income, FY2024: −270.21M USDOperating income, FY2025: −438.15M USDOperating income, FY2026: −532.9M USDNet income, FY2022: −156.73M USDNet income, FY2023: −210.96M USDNet income, FY2024: −259.34M USDNet income, FY2025: −413.84M USDNet income, FY2026: −505.61M USDFY2022FY2023FY2024FY2025FY2026
Operating income FY2022 −156.03M USD. Operating income FY2023 −208.28M USD. Operating income FY2024 −270.21M USD. Operating income FY2025 −438.15M USD. Operating income FY2026 −532.9M USD. Net income FY2022 −156.73M USD. Net income FY2023 −210.96M USD. Net income FY2024 −259.34M USD. Net income FY2025 −413.84M USD. Net income FY2026 −505.61M USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Cost of goods sold409K USD————
Gross profit−409K USD————
Research and development456.66M USD360.92M USD212.93M USD160.26M USD101.81M USD
Selling, general, and administrative76.24M USD77.24M USD57.28M USD48.02M USD54.23M USD
Operating expenses532.9M USD438.15M USD270.21M USD208.28M USD156.03M USD
Interest income25.33M USD24.73M USD24.95M USD7.58M USD—
Interest expense———12.48M USD—
Depreciation and amortization409K USD377K USD231K USD193K USD126K USD
Operating income−532.9M USD−438.15M USD−270.21M USD−208.28M USD−156.03M USD
Net income−505.61M USD−413.84M USD−259.34M USD−210.96M USD−156.73M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-4.42%
11 comparable reports
Latest EPS result
-0.75
Estimate -0.63 · Miss by 19.26%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.55-0.63-0.72-0.8Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 6, 2025: actual -0.76, estimate -0.73, surprise -4.11%, Miss. Q2 2025, reported May 29, 2025: actual -0.64, estimate -0.713, surprise +10.27%, Beat. Q3 2025, reported Aug 11, 2025: actual -0.6, estimate -0.69, surprise +13.04%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.73, estimate -0.72, surprise -1.39%, Miss. Q1 2026, reported Feb 6, 2026: actual -0.61, estimate -0.72, surprise +15.28%, Beat. Q2 2026, reported May 20, 2026: actual -0.73, estimate -0.592, surprise -23.31%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.75, estimate -0.629, surprise -19.26%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.73, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates7.38M6.82M6.27M5.72MQ1 '26EstimateQ3 '26MetQ4 '26Estimate
Q1 2026, reported Feb 6, 2026: actual —, estimate 6M USD, surprise —, Comparison unavailable. Q3 2026, reported Aug 6, 2026: actual 7.1M USD, estimate 7.1M USD, surprise 0.00%, Met estimate. Q4 2026, reported Nov 9, 2026: actual —, estimate 7.1M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

23 ratings
Strong buy00%
Buy1878%
Hold417%
Sell14%
Strong sell00%

IMVT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding IMVT

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
119.74M
Weight
1.05%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
100.89M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
96.19M
Weight
0.12%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
72.92M
Weight
0.04%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
42.02M
Weight
0.09%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
35.11M
Weight
0.23%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
34.34M
Weight
0.04%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
26.89M
Weight
0.25%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%

Continue in GoAI

Research IMVT

research.disclaimer